Lipid mixture for infant nutrition

Abstract

The subject invention includes a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said phospholipid and uses thereof.

1 - 47 . (canceled) 
     
     
         48 . A composition, comprising:
 at least one triglyceride comprising a compound of formula I:   
       
         
           
           
               
               
           
         
         wherein R 1 , R 2  and R 3  may be identical or different and are each independently selected from the group consisting of H or an acyl group, wherein the acyl group is selected from the group consisting of a saturated fatty acid, mono-unsaturated fatty acid and long chain poly-unsaturated fatty acid (LC-PUFA) residues; and 
         at least one long chain poly-unsaturated fatty acid (LC-PUFA); and 
         at least one phospholipid comprising a compound of formula II: 
       
       
         
           
           
               
               
           
         
         Wherein R 4  and R 5  are each a substituent having independently the meanings of R 1 , R 2 , R 3 ; and in which 
         R 6  is selected from a group consisting of choline, inositol, ethanolamine and serine; 
         Wherein at least 1% of the LC-PUFA in the composition is conjugated to at least one phospholipid; 
         And wherein the LC-PUFA's in the composition comprising arachidonic acid (AA) and docosahexaenoic acid (DHA) conjugated to triglycerides, and to phospholipids, with the weight content of AA in the composition being larger than that of DHA. 
       
     
     
         49 . A composition according to  claim 48 , comprising (a) two or more triglycerides of formula I; (b) two or more phospholipids of formula II; (c) long-chain polyunsaturated fatty acids (LC-PUFA's); the LC-PUFA's comprising (i) free LC-PUFA's, (ii) LC-PUFA's conjugated to the triglycerides, and (iii) LCPUFA's conjugated to the phospholipids. 
     
     
         50 . A composition according to  claim 48 , wherein at least about 2% of the LC-PUFA content of the composition is conjugated to said at least one phospholipid. 
     
     
         51 . A composition according to  claim 48 , wherein the weight content ratio between AA and DHA is at least about 1.1. 
     
     
         52 . A composition according to  claim 48 , wherein R 5  is an LC-PUFA residue. 
     
     
         53 . The composition of  claim 52  wherein the LC-PUFA residue comprises a docosahexaenoic acid (DHA) or arachidonic acid (AA). 
     
     
         54 . A composition according to  claim 48 , wherein R 4  is an LC-PUFA residue. 
     
     
         55 . A composition according to  claim 48 , wherein the total amount of phospholipids is at least about 5%. 
     
     
         56 . A composition according to  claim 55 , wherein the total amount of phospholipids is at least about 7%. 
     
     
         57 . A composition according to  claim 56 , wherein the total amount of phospholipids is at least about 10%. 
     
     
         58 . A composition according to  claim 57 , wherein the total amount of phospholipids is at least about 15%. 
     
     
         59 . A composition according to  claim 58 , wherein the total amount of phospholipids is at least about 20%. 
     
     
         60 . A composition according to  claim 48  further comprising at least one triglyceride of formula I, having at least 30% (w/w) of total palmitic acid conjugated at the sn-2 position. 
     
     
         61 . A composition according to  claim 48  further comprising at least one triglyceride of formula I having the following conjugated fatty acid profile
 0-10% C8:0 fatty acids out of the total fatty acids; 
 0-10% C10:0 fatty acids out of the total fatty acids; 
 0-22% C12:0 fatty acids out of the total fatty acids; 
 0-15% C14:0 fatty acids out of the total fatty acids; 
 15-55% C16:0 fatty acids out of the total fatty acids of which at least 30% is conjugated at the sn-2 position of triglyceride; 
 1-7% C18:0 fatty acids out of the total fatty acids; 
 20-75% C18:1 fatty acids out of the total fatty acids; 
 2-40% C18:2 fatty acids out of the total fatty acids; 
 0-8% C18:3 fatty acids out of the total fatty acids; and 
 other fatty acids present in levels of less than 8% of the total fatty acids. 
 
     
     
         62 . A composition selected from the group consisting of a pharmaceutical, a nutraceutical, a functional food and an infant formula, the composition comprising the composition of any one of  claims 48  to  61 . 
     
     
         63 . A method for improving, promoting or maintaining the development of cognitive functions or the development of brain and retina or the development of visual acuities or the development of CNS in a subject comprising administering to said subject a composition of any one of  claims 48  to  61 . 
     
     
         64 . A method for improving, promoting or maintaining the growth quality or intestinal maturity of a subject by administering to said subject a composition of any one of  claims 48  to  61 .